Intuitive Surgical, Inc.
ISRGIntuitive Surgical, Inc.'s earnings have outrun its stock. EPS grew +22.6% in a year against a −27.0% price move.
The sharpest disagreement: annual EPS moved +22.6% against a −27.0% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (27 weeks in) while the P/E sits at the 0th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +18.6% year on year, and 103% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Intuitive Surgical, Inc. trades at $362, in a downtrend and 27 weeks into that stage. That is −25.1% against its own 200-day average. It sits at 10% of a 52-week range of $338 to $586. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (28 weeks and counting).
Today the stock is in a downtrend — week 27 of stage 4. At $362 it trades −25.1% versus its 200-day average and sits at 10% of its 52-week range ($338–$586).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +380% while the S&P 500 moved +248% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (28 weeks and counting; last ahead the week of 2026-01-16) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 0th percentile of its own range.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Intuitive Surgical, Inc. trades at 41.5× P/E, about the cheapest it has ever traded. Its long-run median P/E is 71.7×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 41.5× is about the cheapest it has ever traded, against a long-run median of 71.7× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +22.6% against a −27.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +3.5%/yr price move, ~+27.4%/yr came from earnings growth and ~−23.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Intuitive Surgical, Inc. reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.9% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +20.5% | +17.4% | — | — |
| Profit | +23.1% | +29.1% | — | — |
| EPS | +22.6% | +29.2% | — | — |
| Stock price | −27.0% | +3.5% | +1.8% | +16.7% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
47.8/100 — rank 15 of 30 in Medical Instruments & Supplies · 53% evidence confidence
Intuitive Surgical, Inc. scores 47.8 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 15. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 22 + 15.9 + 9.7 + 0.2 = 47.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Intuitive Surgical, Inc. reported $2.8 B of revenue in the Mar 26 quarter, +23.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 15.2% a year. The last full year, FY25, came in at $10.1 B. The last four reported quarters add to $10.6 B.
Intuitive Surgical, Inc. reported $2.8 B of revenue in the Mar 26 quarter, +23.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 15.2% a year. The last full year, FY25, came in at $10.1 B. The last four reported quarters add to $10.6 B.
FY25 revenue came in at $10.1 B (+20.5% on the year), capping 4 years at 15.2% compound. The latest quarter (Mar 26) printed $2.8 B, +23.1% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +21.6% growth against the decade's 15.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +21.6% over the last 4 quarters against +20.3%/yr over the last 8 — stabilising; TTM profit +20.5% vs +22.2%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 31.0% this quarter (+5.2 pp YoY).
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Intuitive Surgical, Inc.'s operating margin is 31.0% in the Mar 26 quarter, +5.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 24.9% to 31.9%. The current quarter sits inside that band.
Intuitive Surgical, Inc.'s operating margin is 31.0% in the Mar 26 quarter, +5.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 24.9% to 31.9%. The current quarter sits inside that band.
The latest quarter's operating margin is 31.0%, +5.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 24.9%–31.9%.
Why the margin moved: operating margin went +5.2 pp year on year while gross margin went +1.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins held — did that reach the bottom line? Next: profit +18.6% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Intuitive Surgical, Inc. earned $0.8 B of net profit in the Mar 26 quarter, +18.6% year on year. It is the 12th consecutive quarter of growth. Full-year FY25 profit was $2.9 B. The 4-year compound rate is 13.6%. That is 30.0% of the quarter's revenue. The same quarter a year earlier earned $0.7 B.
Intuitive Surgical, Inc. earned $0.8 B of net profit in the Mar 26 quarter, +18.6% year on year. It is the 12th consecutive quarter of growth. Full-year FY25 profit was $2.9 B. The 4-year compound rate is 13.6%. That is 30.0% of the quarter's revenue. The same quarter a year earlier earned $0.7 B.
Mar 26 profit was $0.8 B, +18.6% year on year — the 12th consecutive quarter of growth. On the full year, FY25 printed $2.9 B (+23.1%), and the 4-year compound rate is 13.6%.
Why profit moved: revenue contributed +23.1% and the margin +5.2 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +20.9% vs revenue +21.6%. Profit and revenue are moving roughly in step.
→ Profit rose — but did the cash follow? Next: 103% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 103% of Intuitive Surgical, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $3.0 B of operating cash against $2.9 B of profit. After $0.5 B of capital spending, $2.5 B was left as free cash.
FY25: operating cash of $3.0 B against reported profit of $2.9 B, leaving free cash of $2.5 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 103% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
→ So follow the cash to where it goes. Next: $3.0 B of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Intuitive Surgical, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $3.0 B over the last 3 years. Averaged over those years that is 9.9% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $3.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROE is 17% and the ROIC − WACC spread is +9.6 pp.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Intuitive Surgical, Inc. earns a ROE of 16% in FY25. That is up from a trough of 12% in FY22. Return on invested capital clears the cost of that capital by +9.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 28.6% net margin on 0.49× asset turns.
FY25 ROE is 16%, recovered from a FY22 trough of 12% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 28.6% net margin × 0.49× asset turns × 1.14× balance-sheet leverage ≈ 16.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 21.9% − 12.3% = a +9.6 pp spread. The 12.3% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is not in our numbers.
Dividend
Intuitive Surgical, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Intuitive Surgical, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
→ No payout to follow. The cash question becomes what the business does with what it earns instead.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
A borrowings history is not in our numbers for this stock.
A borrowings history is not in our numbers for this stock, so this section says that plainly rather than working around it.
→ Who owns this, and are they adding or leaving? Next: short interest is 1.9% of the float.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.9% of Intuitive Surgical, Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 2.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.9% of the float is sold short, and at typical trading volumes it would take about 2.4 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Intuitive Surgical, Inc.: the Z-score reads 42.45. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 42.45 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 42.45.
Frequently asked questions
What is Intuitive Surgical, Inc.'s stock price today?
Intuitive Surgical, Inc. trades at $362, −27.0% over the past year. The company is valued at $128 B. The stock sits at 10% of its 52-week range of $338–$586, −25.1% versus its 200-day average. On the tape, the price is in a downtrend, 27 weeks in. — as of 29 July 2026.
What were Intuitive Surgical, Inc.'s latest quarterly results?
Intuitive Surgical, Inc. reported revenue of $2.8 B and net profit of $0.8 B for the Mar 26 quarter. Revenue rose 23.1% and profit rose 18.6% year on year. Earnings per share were $2.28. The operating margin was 31.0%, 5.2 pp higher than a year earlier. — as of 29 July 2026.
What is Intuitive Surgical, Inc.'s revenue?
Intuitive Surgical, Inc. reported revenue of $2.8 B in the Mar 26 quarter, +23.1% year on year. For the full FY25 fiscal year, revenue was $10.1 B (+20.5%). Over the last 4 years revenue compounded at 15.2% a year. — as of 29 July 2026.
What is Intuitive Surgical, Inc.'s profit?
Intuitive Surgical, Inc. earned $0.8 B of net profit in the Mar 26 quarter, +18.6% year on year — the 12th straight quarter of growth. Full-year FY25 profit was $2.9 B. The operating margin ran 31.0% in the latest quarter. — as of 29 July 2026.
What is Intuitive Surgical, Inc.'s market cap?
Intuitive Surgical, Inc.'s market capitalisation is $128 B at a stock price of $362. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 29 July 2026.
What is Intuitive Surgical, Inc.'s P/E ratio?
Intuitive Surgical, Inc. trades at a P/E of 41.5×, at the 0th percentile of its own 4-year range, against a long-run median of 71.7×. This is a comparison with the stock's own history, not a value call — as of 29 July 2026.
Does Intuitive Surgical, Inc. pay a dividend?
No — Intuitive Surgical, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 29 July 2026.
Is Intuitive Surgical, Inc. overvalued?
On its own history, Intuitive Surgical, Inc. looks cheap against its own history: its P/E of 41.5× has been cheaper only 0% of the time in 4 years (long-run median 71.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 29 July 2026.
Is Intuitive Surgical, Inc. growing?
Yes — Intuitive Surgical, Inc. is growing: latest-quarter revenue +23.1% year on year, profit +18.6%, and the margin +5.2 pp at 31.0%. The 4-year compound rates are 15.2% (revenue) and 13.6% (profit). The earnings engine currently reads: improving — as of 29 July 2026.
How is Intuitive Surgical, Inc. performing?
Intuitive Surgical, Inc. is in a downtrend, 27 weeks in. Its latest quarter's revenue rose 23.1% and profit rose 18.6% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 28 weeks. This describes what the data did, not a rating. — as of 29 July 2026.
What stage is Intuitive Surgical, Inc. in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.9% and holding. The read comes from the last 12 quarters of growth (revenue growth +21.6% latest, profit growth +20.5% latest, eps growth +21.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 29 July 2026.
Is Intuitive Surgical, Inc. in an uptrend?
No — the price is in a downtrend (week 27 of stage 4), trading −25.1% versus its 200-day average and at 10% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 29 July 2026.
Is Intuitive Surgical, Inc. beating the market?
Not lately — on a trailing-13-week view Intuitive Surgical, Inc. is currently behind the S&P 500 (28 weeks and counting; last ahead the week of 2026-01-16), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +380% against the S&P 500's +248% — ahead of the index over the full window. — as of 29 July 2026.
Will Intuitive Surgical, Inc.'s stock price go up?
This page publishes no price forecast for Intuitive Surgical, Inc. What it measures instead: the stock price is $362, the price is in a downtrend 27 weeks in. Its P/E of 41.5× sits at the 0th percentile of its own 4-year range. — as of 29 July 2026.
Is the market betting against Intuitive Surgical, Inc.?
No — short interest is 1.9% of Intuitive Surgical, Inc.'s tradable float, about 2.4 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 29 July 2026.
What is Intuitive Surgical, Inc.'s capex?
Intuitive Surgical, Inc. spent $3.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 29 July 2026.
What is Intuitive Surgical, Inc.'s cash flow?
Intuitive Surgical, Inc. generated $3.0 B of operating cash flow in FY25 and $2.5 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $2.9 B, so operating cash ran ahead of profit. — as of 29 July 2026.
Is Intuitive Surgical, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 103% of Intuitive Surgical, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $3.0 B against reported profit of $2.9 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 29 July 2026.
How financially safe is Intuitive Surgical, Inc.?
On the balance sheet, the Z-score reads 42.45 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 29 July 2026.
Where is Intuitive Surgical, Inc. in its business cycle?
Intuitive Surgical, Inc.'s FY25 operating margin was 29.3%, against a 5-year band of 24.9%–31.9%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 31.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 29 July 2026.
What could break the Intuitive Surgical, Inc. story?
The sharpest disagreement: annual EPS moved +22.6% against a −27.0% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 29 July 2026.
Is Intuitive Surgical, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Intuitive Surgical, Inc.'s earnings have outrun its stock. EPS grew +22.6% in a year against a −27.0% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 29 July 2026.